Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Micron Technology, Inc. — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B), while Micron Technology, Inc. trades at $880.42 (market cap $1.03T). The key difference: Micron Technology, Inc. is far larger — about 116× Kymera Therapeutics Inc. Common Stock's market cap, and Micron Technology, Inc. pays a 0.07% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Micron Technology, Inc. for 49 Days on average.
| KYMR | MU | |
|---|---|---|
Market Cap | $8.88B | $1.03T |
Volume | 1,028,790 | 27,296,988 |
Sector | Health | Technology |
52-Week High | $127.31 | $1.21K |
52-Week Low | $55.80 | $191.94 |
Typical Hold Time | 0 Days | 49 Days |
Enterprise Value | $8.27B | $996.01B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Micron Technology (MU) trades at $953.19, down 3.62% on the day, amid strong fundamentals including a P/E of 12.82 and net income margin of 63.8%. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $33.42 exceeding expectations. Technical indicators show a bullish moving average signal but neutral oscillators, with support at $954. Revenue surged to $37.38 billion in 2025, and cash flow from operations reached $17.53 billion, reflecting robust operational performance.
Outlook remains positive driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030. Risks include cyclical memory pricing and potential growth deceleration. Analyst consensus is strongly bullish with an average price target of $1,590, suggesting significant upside. Institutional sentiment supports growth, but investors should monitor competitive pressures and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
